Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology

Langue : anglais

Edité par Cold Spring Harbor Laboratory Press,U.S., 2022

1621824683 / 9781621824688

Vendeur : World of Books (was SecondSale), Montgomery, IL, Etats-UnisWorld of Books (was SecondSale)

Vendeur avec une évaluation de 5 étoiles

Vendeur AbeBooks depuis 20 décembre 2007

Livre relié

Etat: Occasion - Assez bon

EUR 3,46

 Frais de port gratuits 
Expédition nationale : Etats-Unis

Quantité disponible : 1 disponible

Ajouter au panier
Retours gratuits sous 30 jours

A propos de cet article

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

N° de réf. du vendeur 00107492356

Titre
Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology
Auteur
James A Geraghty
Éditeur
Cold Spring Harbor Laboratory Press,U.S.
Année de publication
2022
État de l'article
Very Good
Reliure
Hardback
Langue
anglais
ISBN à 10 chiffres
1621824683
ISBN à 13 chiffres
9781621824688

World of Books (was SecondSale)

Montgomery, IL, Etats-Unis

Vendeur avec une évaluation de 5 étoiles

Vendeur AbeBooks depuis 20 décembre 2007

Frais d'expédition à l'intérieur de ce pays : Etats-Unis

Article4 à 12 jours ouvrés3 à 6 jours ouvrés
Premier articleEUR 0,00EUR 9,73
Les délais de livraison sont fixés par les vendeurs et varient en fonction du transporteur et du lieu. Les commandes transitant par les douanes peuvent être retardées et les acheteurs sont responsables de tous les droits ou frais associés. Les vendeurs peuvent vous contacter au sujet de frais supplémentaires afin de couvrir toute augmentation des coûts d'expédition de vos articles.

Modes de paiement

  • Visa
  • Mastercard
  • American Express
  • Carte Bleue
  • Apple Pay
  • Google Pay

Description de la boutique

Founded in 2002, World of Books is a leading online destination for buying and selling both preloved and new books, committed to making sustainable reading accessible to all. With a mission to help people read more and waste less, World of Books offers a huge range of affordable, high-quality books — giving both new and preloved titles a second life. The company also operates World of Books – Sell Your Books, an easy-to-use platform that allows customers to trade in unwanted books for cash, helping to keep books in circulation while promoting sustainability. As a Certified B Corp, World of Books is driven by a vision to become the world’s largest and most sustainable dedicated online bookstore. The company measures its success through the positive environmental impact it creates, the value it provides to customers, and its ability to operate profitably while supporting its sustainable mission …

Profil professionnel du vendeur

SBYB, Inc.

900 Knell Rd
Montgomery, IL Etats-Unis 60538